Equivalent Dose Research Articles

Extracellular vesicles derived from endothelial progenitor cells modified by Houshiheisan promote angiogenesis and attenuate cerebral ischemic injury via miR-126/PIK3R2.

Angiogenesis following cerebral ischemia is crucial for restoring blood supply to the ischemic region. Extracellular vesicles (EVs) derived from endothelial progenitor cells (EPCs) offer potential therapeutic benefits in the treatment of cerebral ischemia. Houshiheisan (HSHS) has been shown to improve clinical outcomes in ischemic stroke patients, reduce cerebral ischemic damage in rats, and protect endothelial cells. However, the potential effects of HSHS-modified EPC-derived EVs (EVsHSHS) for cerebral ischemia remain unexplored. This study investigated the impact of EVsHSHS on angiogenesis using rats with permanent middle cerebral artery occlusion (pMCAO) and brain microvascular endothelial cells (BMECs) subjected to oxygen-glucose deprivation (OGD). Results demonstrated that EVsHSHS promoted the proliferation, migration, and tube formation of BMECs in vitro. In vivo, high doses of EVsHSHS exhibited better performance than equivalent doses of unmodified EPC-derived EVs in reducing cerebral infarction volume, improving cortical blood perfusion, decreasing neurological deficit scores, and increasing cortical microvessel density at day 7 post-modeling. The pro-angiogenic effects of EVsHSHS following cerebral ischemia were associated with the regulation of miR-126 and the PIK3R2/PI3K/AKT pathway.

Personalized Adjunctive Hemoperfusion Therapy for Refractory Septic Shock Caused by Vibrio Cholerae in Thalassemia Patient

This case report describes a patient with Beta-thalassemia/hemoglobin E that developed Vibrio cholerae septicemia, leading to refractory septic shock with a maximum norepinephrine equivalent dose of 1.84 µg/kg/min and multi-organ failure. As the patient remained in refractory shock despite receiving proper antibiotics and organ support for 48 hours, adjunctive therapy including, HA330 hemoperfusion, was initiated. Shock reversal and significant reduction of inflammatory cytokines were achieved after two intervention sessions. The patient was discharged home, despite an initial predicted mortality rate of 85% based on Acute Physiology and Chronic Health Evaluation II (APACHE II).

Efficacy and safety of safinamide in Parkinson's disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study.

This multicentre, prospective, single-arm study evaluated safinamide as add-on therapy to levodopa in Korean patients with Parkinson's disease (PD) with motor fluctuations with≥1.5 h of "off" time daily, who took levodopa≥3 times/day (n = 199). Baseline levodopa and dopamine agonist doses were maintained without escalation during the 18-week treatment period. Participants received safinamide 50 mg/day for 2 weeks and 100 mg/day thereafter. PD diaries and questionnaires (Parkinson's Disease Questionnaire, PDQ-39; Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, MDS-UPDRS part 3 and part 4; King's Parkinson's Disease Pain Scale, KPPS; Mini-Mental State Examination, MMSE) were assessed at baseline and at week 18. Treatment-emergent adverse events (TEAEs) were recorded. Mean disease duration was 6.6 years, and mean levodopa equivalent daily dose was 721.1 mg/day. At week 18, significant improvements from baseline were seen for the co-primary endpoints, mean daily "off" time (-1.3±2.4 h, p<0.001) and quality of life (QoL) based on PDQ-39 summary index (-2.7±10.3, p<0.001), Moreover, significant improvements were seen in motor symptoms and motor complications (MDS-UPDRS part 3 and 4), daily "on" time without dyskinesia (all p<0.001) and pain (KPPS; p = 0.013). TEAEs occurred in 40.2% of patients, with most being mild in severity. In conclusion, safinamide at a dosage of 100 mg/day significantly improved motor symptoms, QoL, and pain, and demonstrated a favourable safety profile without levodopa dosage escalation during the 18-week treatment period in Korean patients with PD.Trial registration number and date: NCT05312632, First Posted: April 5, 2022.

Assessment of air dose distribution in the vertical plane for better occupational exposure management.

The International Commission on Radiological Protection recommended a significant reduction of the equivalent dose limit for the eye lens. Reportedly, medical staff in charge of diagnostic imaging procedures may exceed the new dose limits for the eye lens. The use of dosimeters dedicated to the eye lens remains low, and dosimeters for the neck region were often used to assess eye lens doses. However, measurements by neck badges may overestimate or underestimate the recommended eye lens doses because the height of the neck differs from that of the eye. This study aimed to evaluate the air dose distribution in the vertical plane to understand the difference between neck and eye doses. H*(10) in the height of the eye position was 52.8% lower than that in the height of the neck position in the under-table position. Thus, the equivalent eye lens dose evaluated using a neck badge dosimeter may be overestimated.

Bilateral erector spinae plane block on opioid-sparing effect in upper abdominal surgery: study protocol for a bi-center prospective randomized controlled trial.

Erector spinae plane block (ESPB) is a promising technique for effective analgesia. It is still uncertain if ESPB offers the same opioid-sparing effect as thoracic paravertebral block (PVB) in midline incision for upper abdominal surgery. The study is a prospective, bi-center, randomized, controlled, non-inferior trial. One hundred fifty-eight patients scheduled for upper abdominal surgery will be randomly assigned to receive bilateral ESPB or PVB before surgery. The primary outcome will be the equivalent cumulative analgesia dosage of sufentanil during the surgery, which is defined as the total dosage of sufentanil from anesthesia induction to tracheal extubation. The main secondary outcomes include postoperative complications and the quality of recovery-15 score at 24h, 48h, and 30days after surgery. This study will assess the opioid-sparing efficacy of ESPB and PVB, complications, and the quality of recovery of two blocks. ChiCTR2300073030 ( https://www.chictr.org.cn/ ). Registered on 30 June 2023.

Effect of remimazolam toluene sulfonate on the cognitive function of juveniles and its mechanism of action.

Remimazolam is a new benzodiazepine. Currently, it remains unclear how repeated exposure to remimazolam affects the cognitive function of the developing brain. In the present study, the equivalent doses of the two sedatives were derived from S-shaped dose-response curves, and the ED95 of remimazolam was 45mg/kg (95% CI 37.579-79.280), and for midazolam, it was 77mg/kg (95% CI 63.751-127.21) using probability analysis. Then, we evaluated the effects of remimazolam and midazolam on cognitive function in juvenile mice (C57BL/6) through Y-maze and MWM. TUNEL staining was used to observe the apoptosis of neurons in hippocampus, western blotting was used to detect the expression changes of related proteins, and the changes of LTP were observed by recording the activity of neurons through electrical stimulation. We found that there was no significant difference in the behavior of mice in MWM. However, the short-term memory of developing mice was impaired in Y-maze after repeated exposure to remimazolam and midazolam. Furthermore, our data demonstrated that the short-term memory damage caused by remimazolam is lighter than midazolam. Concurrently, the extent of caspase-3 upregulation, the number of neuronal apoptosis in CA1 and CA3 regions, a downward trend of PSD95 and BDNF in the hippocampus, and the inhibition of LTP were highly consistent with the behavior of short-term memory impairment. These results indicate that the degree of memory impairment caused by remimazolam is milder than that caused by midazolam, making it a potential replacement for midazolam in repeated medication and long-term sedation in children.

Interpreting depositional environments from modern floodplain sediments using optically stimulated luminescence

We investigate how luminescence signals imprinted on fluvial sediments vary depending on the depositional environment and vary through time in the same river. We collected sediment samples from four geomorphically distinct locations on the modern floodplain and modern point bar on the Buffalo River in northwest Arkansas, USA, in order to determine if different depositional environments are associated with distinct bleaching characteristics in the sediments. Our analysis revealed that all samples from different depositional environments yielded ages consistent with modern deposition. The samples collected from the floodplain and bar head contained a higher proportion of grains with residual doses, indicative of incomplete bleaching during transport, while samples from the mid‐bar and bar tail appeared well bleached. Our results are particularly intriguing for two significant reasons. First, they highlight distinct equivalent dose distributions in different depositional environments. Second, they shed light on an intriguing relationship: despite generally well‐bleached modern floodplain samples, ancient sediments from corresponding terraces displayed equivalent dose (De) distributions that suggest partial bleaching in some cases. This research contributes to the growing body of work that seeks to establish a relationship between luminescence properties and sediment transport processes and offers valuable insight into how luminescence signals vary locally in modern fluvial deposits, which can help guide the interpretation of older fluvial deposits.

External validation of a modified cardiovascular sequential organ failure assessment score in patients with suspected infection using the MIMIC-IV database.

We developed a modified cardiovascular (CV) Sequential Organ Failure Assessment (SOFA) score using an emergency department-based cohort data, incorporating norepinephrine equivalent dose and lactate to represent current clinical practice patterns for vasopressor utilization and the diagnostic significance of lactate, respectively. In this study, we sought to validate this modified CV-SOFA score in intensive care unit patients with suspected infection using the Marketplace for Medical Information in Intensive Care (MIMIC)-IV database. This was a retrospective study that utilized data from the MIMIC-IV database. Modified CV/total SOFA score and original CV/total SOFA score were compared for predicting in-hospital mortality. Area under the receiver operating characteristic curve (AUROC) and the calibration curve were employed to evaluate discrimination and calibration, respectively. A total of 29,618 ICU patients with suspected infections was analyzed. The in-hospital mortality rate was 12.4% (n = 3,675). Modified CV-SOFA score (AUROC 0.667; 95% confidence interval [CI] 0.657-0.677 vs. 0.663; 95% CI 0.654-0.673; p = 0.283) and modified total SOFA score (0.784 [95% CI 0.776-0.793] vs. 0.785 [95% CI 0.777-0.793], p = 0.490) did not differ significantly from the original CV-SOFA score and original total SOFA score, respectively. The calibration curve of the original CV-SOFA score was inferior to that of the modified CV-SOFA score. The modified CV- and total SOFA scores were better calibrated than the original CV- and total SOFA scores, but their discriminative performance was not significantly different. Further studies of the modified CV-SOFA score in different settings and populations are required to assess the generalizability of this score.

RADT-37. PROTON THERAPY REIRRADIATION FOR RECURRENT MALIGNANT GLIOMA: PROSPECTIVE ANALYSIS FROM THE PROTON COLLABORATIVE GROUP

Abstract BACKGROUND Standard of care treatment for recurrent malignant glioma after prior radiotherapy (RT) is not well established. Proton therapy (PT) is increasingly used for reirradiation (ReRT) at the time of recurrence; however, treatment outcomes, toxicity, and prognostic factors for patients treated with PT-ReRT remain poorly defined. METHODS The prospective, multi-institutional Proton Collaborative Group (PCG) registry was queried for patients with malignant glioma who previously received RT and underwent PT-ReRT between 7/2011-12/2023. Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan-Meier method, and Cox proportional hazards regression was used for uni- and multivariate analysis (UVA and MVA). Dose was calculated using equivalent dose in 2-Gy fractions (EQD2). RESULTS 143 consecutive patients were identified. Median follow-up was 11.2 months and median time interval (TI) from prior RT (median 58.5 Gy) to PT-ReRT (median 44.6 Gy) was 42.4 months. Primary histology was glioblastoma (n=74), astrocytoma (n=35), and oligodendroglioma (n=34). Median PFS and OS were 8.1 and 11.2 months, respectively. On UVA, improved OS was associated with oligodendroglioma (HR 0.37) and astrocytoma histology (HR 0.53) compared to glioblastoma, TI &amp;gt;60 months (HR 0.2), CNS WHO Grade 2 compared to 4 (HR 0.42), and ECOG performance status 0 (HR 0.47). On MVA, improved OS remained associated only with oligodendroglioma (HR 0.42) and TI &amp;gt;60 months (HR 0.49). Acute and Late Grade 3 toxicity occurred in 7% and 4% of patients. Acute Grade 3 toxicity was associated with poor performance status (HR 16.15). CONCLUSIONS In the largest series of glioma PT-ReRT reported to date, retreatment appears well tolerated with variable outcomes based on clinical prognostic factors. Toxicity rates were acceptable compared to historical photon-based literature despite a high median prescription dose.

DDDR-39. PI3 KINASE AND CHECKPOINT INHIBITION: A POTENTIALLY NOVEL THERAPEUTIC STRATEGY FOR GLIOBLASTOMA (GBM)

Abstract Glioblastoma is the most common and aggressive malignant brain tumor with a median survival of less than 2 years, highlighting the need for more effective therapeutics. Dual pathway synergism between PI3K inhibitors and check-point inhibitors is a promising therapeutic avenue that has not been explored. Based on this possibility, we hypothesized that the combination of PI3K and checkpoint inhibitors will improve survival in our native glioblastoma mouse model. Treatment with GCT-007, a small molecule PI3K inhibitor, induces growth arrest of GBM cells that is accompanied by increases in the cell surface expression of molecules targeted by the immune system and immunotherapy drugs, including MHC Class II and PD-L1. Treatment of mouse GL261 and human U251 GBM cell lines with GCT-007 caused growth arrest, increased the cell surface expression of PD-L1 and MHC class II, and synergized with radiation to cause growth arrest and cell death. We compared GCT-007 to Paxalisib in our in vitro studies and observed that GCT-007 outperformed Paxalisib at increasing MHC class II and PD-L1 expression on the tumor cells at equivalent doses. We then performed in vivo animal studies using our native mouse GBM model. We treated mice orally with GCT-007 and observed a significantly prolonged survival compared to placebo. Mice treated with anti-PD1 resulted in a sexually dimorphic response consisting of prolonged remission of all female mice, now surviving beyond 1 year, but no improvement in the survival of male mice compared to placebo. Adding GCT-007 to anti-PD1 did not alter the prolonged remission outcome in female mice, it did result in prolonged remission of 25% of the male mice, now beyond 1 year. In conclusion, these results indicate that GCT-007 treatment alone improves survival in our native GBM mouse model and it may also improve the response to immune checkpoint inhibitor therapy in at least a fraction of GBM tumors. These data warrant further investigation as a potentially novel therapeutic approach to GBM.

RADT-45. INTEGRATION OF FUNCTIONAL MAGNETIC RESONANCE IMAGING INTO STEREOTACTIC RADIOSURGERY PLANNING TO REDUCE SYMPTOMATIC RADIATION NECROSIS

Abstract BACKGROUND Radiation necrosis (RN) is a common complication of stereotactic radiosurgery (SRS). Functional magnetic resonance imaging (fMRI) localizes eloquent cortical areas for neurosurgical planning but is seldom applied to SRS. We explored the relationship between symptomatic RN and functional neuroanatomy on fMRI. We evaluated the potential benefit of reducing radiation dose to functional areas. METHODS From 2011 to 2022, patients with an fMRI within 3 months of SRS for resected or unresected brain metastases (BM) were included. The BM nearest to the primary motor, language, or visual cortices was designated as the index BM. The functional area on fMRI nearest to the index BM was designated as the fOAR. Focally symptomatic RN (FSRN) was defined as radiographic RN alongside new or worsening focal neurologic symptoms consistent with the fOAR. Patients treated with 5-fraction SRS and modern planning techniques after 2013 were included in the dosimetric analysis. Associations between fOAR dose and FSRN were evaluated with logistic regression. SRS replanning was performed to determine if fOAR dose could be reduced without sacrificing target coverage. RESULTS Among 94 patients, 82% received SRS postoperatively, and 71% received 5-fraction SRS. fOARs included the primary motor (77%), language (19%), and visual (2%) cortices. Of 20 patients with radiographic RN, 20% were neurologically asymptomatic, 20% had anatomically unrelated neurologic symptoms, and 60% had FSRN. The dosimetric analysis included 39 patients. The fOAR volume receiving a single-fraction equivalent dose ≥14 Gy (V14Gy) was associated with FSRN at 18 months post-SRS (OR=6.8/mL, p=0.05). Replanning reduced fOAR V14Gy in all cases. The mean reduction was 28%. CONCLUSION Neurologic symptoms of SRS-induced RN reflect nearby functional neuroanatomy on fMRI. Dose reduction to functional areas while maintaining target coverage is consistently achievable and may mitigate symptomatic RN. Integrated fMRI-based SRS planning may protect neurologic function when treating tumors near eloquent areas.

Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trial.

Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) consists of subcutaneous human immunoglobulin G (IgG) 10% with recombinant human hyaluronidase (rHuPH20) and can be administered at the same dose and interval as intravenous IgG (IVIG). fSCIG recently received US approval as maintenance therapy for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and European approval for adults and children with CIDP after stabilization with IVIG. ADVANCE-CIDP 3 (NCT02955355) was an open-label long-term extension of the Phase 3 double-blind randomized placebo-controlled ADVANCE-CIDP 1 study (NCT02549170) that examined fSCIG safety and efficacy as maintenance CIDP therapy. Primary outcomes were safety, tolerability, and immunogenicity. Efficacy was an exploratory outcome. The study provided 220 patient-years of follow-up data from 85 patients. Median (range) exposure was 33 (0-77) months. Patients received fSCIG every 4 weeks (88.2%) or every 3 weeks (11.8%). Median (range) 4-weekly IgG dose equivalent was 64.0 (28.0-200.0) g. Mean (standard deviation) infusion duration was 135.5 (62.8) minutes. Most adverse events (AEs) were mild or moderate and self-limiting. Of the 1406 AEs, only 48 were severe and 30 were serious. fSCIG-related AEs (n = 798) included infusion site reactions such as pain, redness, and pruritus. Three infusions (0.1%) were reduced in rate, interrupted, or stopped due to intolerability. Relapse occurred in 10 of 77 patients (13.0%); annual relapse rate was 4.5%. An anti-rHuPH20 antibody titer ≥1:160 was detected in 14 of 84 patients (16.7%); patients who tested positive (≥1:160) had similar relapse rates versus those who tested negative (16.7% vs. 12.3%, respectively). ADVANCE-CIDP 3 demonstrated favorable fSCIG long-term safety and tolerability consistent with its established safety profile, and a low relapse rate, supporting use as maintenance CIDP treatment.

Ionizing Radiation Dose to the Skin Assessed after Rapid Detection of 232Th in Consumer Products.

After some consumer products indicated elevated levels of 232Th progeny by gamma-ray spectrometry, a microwave digestion and inductively coupled plasma-mass spectrometry (ICP-MS) procedure was implemented for the direct assay of 232Th content to ensure compliance with Federal regulations and guidelines. Levels of 232Th were determined by ICP-MS based on standard calibration using a 205Tl internal standard. The method had a method detection limit (MDL) of 0.15 Bq g-1 and a lower limit of quantification (LLOQ) of 0.65 Bq g-1 for 232Th, making it a suitable confirmatory method following gamma-ray spectrometry. The 232Th activity concentration calculated from the ICP-MS results ranged from 2.0-3.4 Bq g-1 for the kinesiology tape samples and 20 Bq g-1 for the silicone ion bracelet. The VARSKIN+1.0 software program was used to calculate the shallow dose equivalent of ionizing radiation from 232Th and its progeny from the ICP-MS results. The skin dose to the consumer wearing the kinesiology tape ranged from 0.48-1.6 mSv y-1. The skin dose to the consumer with constant wear of the silicone ion bracelet was estimated to be 17 mSv y-1. Although 232Th may be determined indirectly by assay of high abundance gamma rays produced by its progeny, the US Code of Federal Regulations (CFR) requires the direct assay of 232Th for confirmatory analysis. We found this ICP-MS method to be a rapid 232Th confirmatory technique compared to a chemical separation followed by alpha spectrometry procedure.

Importance of sex-dependent differences for dosing selection and optimization of chemotherapeutic drugs.

Background Despite major advances in cancer treatment in the past years, there is a need to optimize chemotherapeutic drugs dosing strategies to reduce toxicities, suboptimal responses, and the risk of relapse. Most cancer drugs have a narrow therapeutic index with substantial pharmacokinetics variability. Yet, current dosing approaches do not fully account for the complex pathophysiological characteristics of the patients. In this regard, the effect of sex on anticancer chemotherapeutic drugs disposition is still underexplored. In this article, we review sex differences in chemotherapeutic drug pharmacokinetics, we suggest a novel approach that integrates sex into the traditional a priori body-surface-area (BSA) dosing selection model and finally, we provide an overview of the potential benefits of a broader use of therapeutic drug monitoring (TDM) in oncology. Summary To date, anticancer chemotherapeutic drugs dosing is most often determined by BSA, a method widely used for of its ease-of-practice, despite criticism for not accounting for individual factors, notably sex. Anatomical, physiological, and biological differences between males and females can affect pharmacokinetics, including drug metabolism and clearance. At equivalent doses, females tend to display higher circulating exposure and more organ toxicities, which has been formally demonstrated at present for about 20% of chemotherapeutic drugs. An alternative could be the Sex-Adjusted-BSA (SA-BSA), incorporating a 10% increase in dosing for males and a 10% decrease for females, though this approach still lacks formal clinical validation. Another strategy to reduce treatment-related toxicity and potentially enhance clinical outcomes could be a more widespread use of therapeutic drug monitoring (TDM), for which a benefit has been demonstrated for 5-fluorouracil, busulfan, methotrexate or thiopurines.

Earlier preoperative percutaneous intercostal cryoanalgesia improves recovery after pectus excavatum surgery

Background and aimsMinimally invasive repair of pectus excavatum is associated with intense postoperative pain. We aimed to evaluate the effectiveness of percutaneous intercostal cryoanalgesia according to the different timing of...

Radiological risk assessment of phosphate fertilizer application on farmlands in Ondo State, Nigeria.

This study assesses the radiological risks associated with phosphate fertilizer application on farmlands in Ondo State, Nigeria. Soil samples from ten agricultural towns were analyzed for radionuclide concentrations using gamma-ray spectrometry. Primordial radionuclides such as 238U, 232Th, and 40K were examined, with 40K showing the highest concentration due to the potassium-rich nature of phosphate fertilizers. Spatial variability in radionuclide concentrations was observed, attributed to agricultural activities. Despite variations, mean activity concentrations were below global averages, indicating low radiological risks. Hazard indices, radium equivalent concentrations, and absorbed dose rates were all within safe limits. The annual effective dose equivalent was significantly lower than recommended levels, and excess lifetime cancer risk estimates were below the global average. The study emphasizes the importance of educating farmers on the potential adverse effects of radionuclides and recommends reducing the use of inorganic fertilizers to promote eco-friendly agricultural practices.

Development of a pharmacokinetic/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis.

This study aimed to develop a suitable osteomyelitis model for pharmacokinetic/pharmacodynamic (PK/PD) evaluation and to investigate the target PK/PD values of vancomycin and tedizolid against methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. An osteomyelitis model was established by implanting an MRSA-exposed sterilized suture in the tibia of normal mice and mice with cyclophosphamide-induced neutropenia. The suitability of the osteomyelitis mouse model for PK/PD evaluation was assessed using vancomycin as an indicator. The target PK/PD values for tedizolid were determined using this model. In neutropenic mice, to achieve a static effect and 1 log10 kill against MRSA, the ratios of the area under the free drug concentration-time curve for 24h to the minimum inhibitory concentration (fAUC24/MIC) of vancomycin were 91.29 and 430.03, respectively, confirming the validity of the osteomyelitis model for PK/PD evaluation. In immunocompetent mice, the target fAUC24/MIC values of tedizolid for achieving a static effect and 1 log10 kill against MRSA were 2.40 and 49.20, respectively. Additionally, only a 0.28 log10 kill was achieved in neutropenic mice with 20 times the human equivalent dose of tedizolid. In patients with restored immunity, tedizolid can potentially be used as an alternative to intravenous vancomycin therapy.

Cardioprotective effects of liposomal resveratrol in diabetic rats: unveiling antioxidant and anti-inflammatory benefits

ABSTRACT As a consequence of chronic hyperglycemia, diabetes complications and tissue damage are exacerbated. There is evidence that natural phytochemicals, including resveratrol, a bioactive polyphenol, may be able to reduce oxidative stress and improve insulin sensitivity. However, resveratrol's limited bioavailability hampers its therapeutic effectiveness. By using liposomes, resveratrol may be better delivered into the body and be more bioavailable. The objective of this study was to assess the cardioprotective potential of liposome-encapsulated resveratrol (LR) in a streptozotocin-induced (STZ) diabetic rat model. Adult male Wistar rats were categorized into five groups: control, diabetic, resveratrol-treated (40 mg/kg), liposomal resveratrol (LR)-treated (20 mg/kg) and liposomal resveratrol (LR)-treated (40 mg/kg) for a five-week study period. We compared the effects of LR to those of resveratrol (40 mg/kg) on various parameters, including serum levels of cardiac markers, tissue levels of pro-inflammatory cytokines, nuclear transcription factor, oxidative stress markers, and apoptotic markers. LR treatment in STZ-diabetic rats resulted in notable physiological improvements, including blood glucose regulation, inflammation reduction, oxidative stress mitigation, and apoptosis inhibition. LR effectively lowered oxidative stress and enhanced cardiovascular function. It also demonstrated a remarkable ability to suppress NF-kB-mediated inflammation by inhibiting the pro-inflammatory cytokines TNF-α and IL-6. Additionally, LR restored the antioxidant enzymes, catalase and glutathione peroxidase, thereby effectively counteracting oxidative stress. Notably, LR modulated apoptotic regulators, including caspase, Bcl2, and Bax, suggesting a role in regulating programmed cell death. These biochemical alterations were consistent with improved structural integrity of cardiac tissue as revealed by histological examination. In comparison, resveratrol exhibited lower efficacy at an equivalent dosage. Liposomal resveratrol shows promise in alleviating hyperglycemia-induced cardiac damage in diabetes. Further research is warranted to explore its potential as a therapeutic agent for diabetic cardiovascular complications and possible cardioprotective effects.

Assessing radioactivity levels in agricultural soil: a comparative study of traditional vs. modern fertilization techniques in Tunisian oases.

To establish a radiological national reference for agricultural soil across Tunisian oases and assess the risk to human health associated with date consumption, with a focus on comparing the impact of traditional and modern fertilization, radiological parameters and activity levels of 22⁶Ra, 232Th, and 4⁰K were determined for 27 oases. These oases were located in three southern Tunisian governorates. The activity concentration of 22⁶Ra, 232Th, and 4⁰K was measured using a 3 × 3 inch NaI(Tl) scintillation detector, which was found to be 21.82 ± 1.0 , 26.51 ± 1.1 , and 559.21 ± 23.0 , respectively, for traditional oases and 26.56 ± 1.2 , 24.45 ± 1.1 , and 661.28 ± 26.3 , respectively, for modern oases. In addition, ambient dose equivalent rate was measured during sampling using a multipurpose hand-held radiation CsI(Tl) detector, which was found to be 0.075 µSv/h in traditional oases and 0.078 µSv/h in modern oases. The resulting radiological parameters and activity concentrations were then compared to results from neighboring countries and the average soil activity worldwide.

A closer look to dose assessment and radiation shielding characteristics of concrete doped magnetite irradiated with 252Cf mixed radiation radionuclide: A Watt Fission approach and Doppler effect

Nuclear radiation emitted by fusion reactors, nuclear power plants, and medical establishments presents potential risks to living organisms personnel, necessitating the implementation of protective measures. To enhance radiation protection for patients workers, various materials can be utilized. Concrete, augmented with various additives, has historically acted as a shielding material. Hence, recent research has predominantly focused on enhancing concrete's ability to attenuate the harmful energy emitted by nuclear sources through modifications to its composition. Accordingly, in the present work, the dose evaluation and radiation shielding characteristics of a range of concrete magnetite (CM) formulations designated as CM-0 (control sample), CM-25, CM-50, CM-75, and CM-100 have been analyzed using MCNPX Monte Carlo (MC) approach and theoretical computations concerning 252Cf mixed radiation radionuclide. In this work, the Watt Fission distribution was employed to derive the neutron spectrum of CM samples, and findings have been thoroughly elucidated in the presence and absence of the specified samples. Then, utilizing the Doppler Effect, the gamma photon spectrum within shielding materials exposed to a spontaneous fission 252Cf source is extracted and characterized. Estimation of Half Value Thickness (HVT) and Mean Free Path (MFP) are provided across a broad spectrum of energy levels. The analysis confirms the successful development of a new type of concrete magnetite (CM) sample that exhibits lower radiation exposure compared to the control sample. This study offers valuable insights into the use of concrete in shielding against mixed radiation radionuclides and opens the door for future research involving similar materials. Specifically, the CM-100 sample demonstrated the lowest half-value thickness (HVT) and provided the most effective reduction of both neutron and gamma radiation. The findings suggest that increasing the concentration of magnetite in concrete greatly enhances its ability to shield against mixed neutron-gamma radiation. This innovation has promising potential for applications in radiation protection, particularly within nuclear reactors and medical facilities. The CM-100 sample showed a notable improvement, achieving an HVT of 0.012 cm and a dose rate reduction of 2.95 × 10−9 Sv.h−1, in contrast to the control sample (CM-0), which had an HVT of 10.358 cm and an equivalent dose rate of 2.84 × 10−9 Sv.h−1. These results underscore the superior shielding properties of the magnetite-doped concrete formulations.